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Abstract
Background: This study was undertaken to estimate utility values for alternative treatment intervals for long acting
antipsychotic intramuscular injections for the treatment of schizophrenia.
Methods: Vignettes were developed using the published literature and an iterative consultation process with
expert clinicians and patient representative groups. Four vignettes were developed. The first was a vignette of
relapsed/untreated schizophrenia. The other three vignettes presented a standardised picture of well-managed
schizophrenia with variations in the intervals between injections: once every 2-weeks, 4-weeks and 3-months.
A standardised time trade off (TTO) approach was used to obtain utility values for the vignettes. As a societal
perspective was sought, a representative sample of individuals from across the community (Sydney, Australia) was
recruited. Ninety-eight people completed the TTO interview. The vignettes were presented in random order to
prevent possible ordering effects.
Results: A clear pattern of increasing utility was observed with increasing time between injections. Untreated
schizophrenia was rated as very poor health-related quality of life with a mean (median) utility of 0.27 (0.20). The
treated health states were rated at much higher utilities and were statistically significantly different (p < 0.001) from
each other: (1) 2-weekly: mean (median) utility = 0.61 (0.65); (2) 4-weekly: mean (median) utility = 0.65 (0.70); (3) 3-
monthly: mean (median) utility = 0.70 (0.75).
Conclusions: This study has provided robust data indicating that approximately a 0.05 utility difference exists
between treatment options, with the highest utility assigned to 3-monthly injections.
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Background
Schizophrenia is a serious mental illness characterized by
symptoms such as hallucinations, delusions, disorganized
communication, poor planning, reduced motivation, and
blunted affect [1]. The incidence of schizophrenia is
around 15.2 per 100,000 persons per year and the lifetime
prevalence is about one percent of any population, irre-
spective of race, gender or social class [2,3]. While this is
relatively low, schizophrenia contributes significantly to
the global burden of disease due to its typical onset in
early adulthood and long-term persistence or fluctuation
of symptoms in around two-thirds of individuals [4].
In 1998, it was estimated that the annual mental health
care costs per individual with schizophrenia in Australia
amounted to $601 million, or $21 600 per individual [5].
When other costs, including lost productivity, were taken
into account, the annual societal cost of schizophrenia
for the Australian urban population was $1.44 billion, or
$51 600 per individual. The relapsing course of schizo-
phrenia in many individuals underlies the significant
societal and personal costs of the disorder. While around
80% of people with schizophrenia recover from their first
e p i s o d eo fi l l n e s s ,a sm a n ya s8 0 %r e l a p s ew i t h i nf i v e
years [6].
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for schizophrenia. However, non-compliance with medica-
tion is a serious problem, with between 40 and 60% of peo-
ple with schizophrenia partially or totally non-compliant
with oral antipsychotics [7,8]. This is associated with poor
treatment outcomes including poor symptom control, loss
of insight, decreased functioning, relapse, and hospital
admission [7]. Long-acting injections (LAIs) were initially
developed in the 1960s in an attempt to guarantee delivery
of prescribed medication thereby improving treatment
outcomes and reducing the risk of relapse due to non-
adherence [9,10].
Data from developed countries suggests that antipsycho-
tic LAIs are used in around 30% of patients with schizo-
phrenia [11]. LAIs are administered by deep intramuscular
injection, either in the deltoid or gluteal muscle, depending
on the formulation available. In Australia, three atypical
LAI antipsychotics have marketing approval, risperidone
(Risperdal Consta
®), olanzapine pamoate monohydrate
(Zyprexa Relprevv
®) and paliperidone palmitate (Invega
Sustenna
®). Risperidone LAI is administered every
2 weeks, olanzapine LAI is administered every 2 or 4 weeks
(depending on the dose), and paliperidone palmitate LAI is
administered every 4 weeks.
Longer injection intervals are expected to improve
health-related quality of life by minimising the frequency
of exposure to deep intramuscular injection pain and the
psychological distress associated with the general fear of
injections. Less frequent injections may also reduce the
disruption to the lives of people with schizophrenia and
their families and carers due to a reduced requirement in
the frequency of travel to outpatient clinics for administra-
tion of a LAI.
Literature searches were conducted concurrently in
Embase and Medline in May 2010 to locate published uti-
lity studies that measured the incremental utility difference
between the administration of long-acting injections for
the treatment of schizophrenia. This search confirmed the
health-related quality of life impact of variations in the
injection frequency for LAI treatment for schizophrenia
had not been studied. Thus, the aim of this study was to
discover whether there was a difference in health-related
quality of life (HRQoL) (utility) between shorter and
longer intervals for antipsychotic LAIs (that is, once every
2 weeks, 4 weeks or 3 months) for the management of
schizophrenia.
Methods
Participants and recruitment
A community sample of 124 individuals was invited to
participate in a time trade-off (TTO) interview. The parti-
cipants were registrants of a market research firm and
were systematically sampled from four geographic regions
across Sydney, Australia. These regions represented a wide
range of sociodemographic characteristics, and a balanced
sample across socioeconomic status, age, and sex was
recruited. In return for their time and travel, respondents
received AUS$45 at the end of each interview. The current
study was a component of a larger study to understand
both the injection pain experience and whether differences
in utility between injection intervals exist. The former
component covering the injection pain experience in schi-
zophrenia patients receiving risperidone LAI as their stan-
dard of care, not reported here, was undertaken to inform
the development of vignettes in the latter part [12]. The
study received ethical approval from the Eastern Health
Research and Ethics Committee and The Alfred Human
Research Ethics Committee. For the time trade off inter-
views specific ethics approval for the study was not
required as the registrants were not patients, no interven-
tions were involved, and they had previously consented
to occasional surveys. Median interview length was
15 minutes.
Vignette preparation and presentation
At interview, each participant was presented with stan-
dardized background information on schizophrenia and
its treatment, together with short descriptions (vignettes
or scenarios) of three health states for people with schi-
zophrenia. These vignettes were designed to be clinically
and domestically realistic, and easily understood. Each of
the vignettes is presented in Figure 1, and can be sum-
marized as follows: (1) a background health state of
untreated schizophrenia, (2) treated schizophrenia with
injections once every 2 weeks, (3) treated schizophrenia
with injections once every 4 weeks, and (4) treated schi-
zophrenia with injections once every 3 months.
An iterative approach was used to develop the vignettes
previously utilised by the research team in similar set-
tings [13]. Vignettes were initially drafted by an experi-
enced researcher (RHO) based upon the literature on the
quality of life of affected individuals, interrogation of
information provided to consumers by a peak consumer
organization (SANE; http://www.sane.org), and through
published studies on the effectiveness of the interven-
tions. The second iteration resulted from careful review
of this initial draft by members of the research team.
Draft vignettes were shown to psychiatrists, members of
the peak consumer organisation, and people currently
treated for schizophrenia to ensure that the descriptions
were clinically accurate, reflected the experiences of the
target population, and accurately represented the neces-
sary dimensions of HRQoL. This included consultation
with people with schizophrenia to derive the terms
describing the pain associated with injection. The proto-
col and specific outcomes for this sub-study will be
reported elsewhere [12]. The pain associated with the
injection was described in a standardised way–moderate
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x KarlisinhismidͲ30sandhasschizophrenia.Heusuallylivesinsupportedaccommodation.
x Karlhearsvoicestellinghimtodothingsthatotherscannothear,aswellasbizarrethoughtsand
imagesofothersspyingandplottingtoharmhim.Heisbecomingwithdrawn,anxiousandunableto
careforhimself,justlikewhenhewasreallysickbefore.Thishasforcedhimtogobackintohospital
fortreatment.
x Notmanypeoplevisithiminhospital,althoughheusuallydoesn’twanttoseeanyoneanyway.Karl
reallywisheshewasbackathomeandfeelingbetter.
x Formanyyears,Karlhasfounditdifficulttostayinapaidjob.
x Karlfeelsverydistressed.
x Hefeelsliketheotherpeopleinthehospitalarewatchinghim,andtalkingabouthimbehindhisback.
Vignette2
x KarlisinhismidͲ30sandhasschizophrenia.Helivesinsupportedaccommodation.
x Hisschizophreniaputslimitsonhisdailylife,butheisgenerallyabletolookafterhimselfandisable
tocompletesomehouseholdchores.
x Heattendssupportgroupmeetingsandappointmentswithhiscounsellor.
x SometimesKarlstillhearsthingsthatnooneelsehears.Hethinkssomeoneiscallinghisnamebut
whenheturnsaround,nooneisthere.Thethingstheysayaren'tscary,likewhenhewasreallysick
before,asthevoicesarejustcallinghisname.Karlstillexperiencessomeparanoidthoughtsbutwith
helpfromhiscounsellorheisabletocopewiththis.
x Karl lacks motivation and drive to look for work, and sometimes doesn’t find pleasure in daily
activities.He sometimes lacks awareness of personal grooming and has difficulty in maintaining
friendships.
x Karlgetsmedicationtohelptreathisschizophrenia.Themedicationisgivenasaninjectionwhichis
longacting.
x Theinjectionisgiveninhisbuttockorarm.Thepainexperiencedwithaninjectionisamoderate
stingingpainthatlastsaboutonehour.
Karlhastotravelbypublictransportonceeverytwoweekstoreceivetheinjection,whichisgivenbya
nurse.
2






Figure3: Meanand95%confidenceintervals(CI)forutilityvaluesforeachtreatment
regimen(0.0=deathequivalenthealthͲrelatedqualityoflife,1.0=fullhealth).

Vignette3
x KarlisinhismidͲ30sandhasschizophrenia.Helivesinsupportedaccommodation.
x Hisschizophreniaputssignificantlimitsonhisdailylife,butheisgenerallyabletolookafterhimself
andisabletocompletesomehouseholdchores.
x Heattendssupportgroupmeetingsandappointmentswithhiscounsellor.
x SometimesKarlstillhearsthingsthatnooneelsehears.Hethinkssomeoneiscallinghisnamebut
whenheturnsaround,nooneisthere.Thethingstheysayaren'tscary,likewhenhewasreallysick
before,asthevoicesarejustcallinghisname.Karlstillexperiencessomeparanoidthoughtsbutwith
helpfromhiscounsellorheisabletocopewiththis.
x Karllacksmotivationanddrivetolookforwork,andsometimesdoesn’tfindpleasureindailyactivities.
Hesometimeslacksawarenessofpersonalgroomingandhasdifficultyinmaintainingfriendships.
x Karlgetsmedicationtohelptreathisschizophrenia.Themedicationisgivenasaninjectionwhichis
longacting.
x Theinjectionisgiveninhisbuttockorarm.Thepainexperiencedwithaninjectionisamoderate
stingingpainthatlastsaboutonehour.
Karlhastotravelbypublictransportonceeveryfourweekstoreceivetheinjection,whichisgivenbya
nurse.
Vignette4
x KarlisinhismidͲ30sandhasschizophrenia.Helivesinsupportedaccommodation.
x Hisschizophreniaputssignificantlimitsonhisdailylife,butheisgenerallyabletolookafterhimself
andisabletocompletesomehouseholdchores.
x Heattendssupportgroupmeetingsandappointmentswithhiscounsellor.
x SometimesKarlstillhearsthingsthatnooneelsehears.Hethinkssomeoneiscallinghisnamebut
whenheturnsaround,nooneisthere.Thethingstheysayaren'tscary,likewhenhewasreallysick
before,asthevoicesarejustcallinghisname.Karlstillexperiencessomeparanoidthoughtsbutwith
helpfromhiscounsellorheisabletocopewiththis.
x Karllacksmotivationanddrivetolookforwork,andsometimesdoesn’tfindpleasureindailyactivities.
Hesometimeslacksawarenessofpersonalgroomingandhasdifficultyinmaintainingfriendships.
x Karlgetsmedicationtohelptreathisschizophrenia.Themedicationisgivenasaninjectionwhichis
longacting.
x Theinjectionisgiveninhisbuttockorarm.Thepainexperiencedwithaninjectionisamoderate
stingingpainthatlastsaboutonehour.
Karlhastotravelbypublictransportonceeverythreemonthstoreceivetheinjection,whichisgivenbya
nurse.
Figure 1 Vignettes used in time trade off interviews.
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Page 3 of 9stinging or throbbing pain that lasts about 1 hour–and
was derived from data obtained from 57 patients with
stable schizophrenia attending an outpatient clinic for
injection of an antipsychotic integral to their standard
care. Consultation on the content of vignettes continued
until consensus was achieved between the researchers,
clinicians, and patient representatives. For each set of
four vignettes, a female set ("Carol”)a n dam a l es e t
("Karl”) were used with participants of the respective
gender.
Time trade-off interviews
Following standard TTO methodology [14,15], partici-
pants were asked systematically to make a series of
hypothetical trade-offs between living in each of the
health states for 10 years, or shorter periods in “normal
health.” Specifically, participants were asked; “Please
consider health state A [one of the test schizophrenia
vignettes] and health state B [normal health for 10
years]. Please consider that you have to live in either
health state for 10 years and then you die. Which health
state would you prefer?” The period of time was varied
for the normal health vignette until the point of indiffer-
ence, where the participant was unable to choose
between 10 years in the alternative health state and the
period of normal health on offer, the participant impli-
citly assigned equivalent value to the alternatives offered.
The “quality” weight then assigned, known as the level
of “utility” in economic evaluation, is the ratio of the
time in normal health on offer to the time in the alter-
native health state (10 years). To avoid ordering bias,
respondents were randomized to respond to either
health state (2), (3) or (4) immediately after their
response to the untreated schizophrenia health state (1).
These health states were not labelled in terms of the
injection interval included and differed only in their
description of the injection interval. The range of possi-
ble utility values was a maximum of 1 for full health
and a minimum of 0 for death.
Interviewers received training for two full days by an
experienced ‘master’ interviewer. This involved theoreti-
cal background, up to eight training interviews with
administrative staff, observation of at least 16 interviews
and accompanying commentary by the trainer. These
initial 16 interviews were undertaken with one inter-
viewer observing to ensure consistency between inter-
viewers. During the study, quality control interviewer
meetings were held after every 20-25 interviews. Given
that the TTO exercise can be difficult for some intervie-
wees and limited relevant data were available to assist
with sample size estimation, 16 initial interviews were
conducted. Investigators and interviewers reviewed each
initial case to identify potential difficulties participants
were having with understanding the TTO technique,
whether interviewers were consistent with their oral pre-
sentation of vignettes and how they reached the point of
indifference, and that the content of the vignettes was
acceptable to participants. No anomalies were revealed,
so no changes were made to the vignettes or procedures.
Sample size
Previous work in the area was used to provide initial esti-
mates of the sample size for the study, notably a study of
TTO-based utility estimates for different treatment
regimes for iron chelation therapy used the same proce-
dures including the same sampling frame [13]. In that
study, very large utility differences between treatment
regimes were identified (oral vs subcutaneous treatments)
with a mean (sd) difference of 0.23 (0.21) in 110 subjects
with paired data (beta = 0.8, alpha = 0.05, SD across vari-
ables from 0.21 to 0.29, correlation between variables r =
0.67). A sample size estimate indicated that such a study
only required about 10 subjects to detect such large dif-
ferences. Given that the likely difference between the
treatment schizophrenia regimes was unknown, but likely
to be smaller, a sample size of approximately 100 was
specified to enable detection of much smaller incremen-
tal differences between health states.
Statistical procedures
The main statistical exercise was to explore the hypoth-
esis that the utility associated with 3-monthly injections
was associated with higher utility than 4-weekly injec-
tions and that those 4-weekly injections were associated
with higher utility than 2-weekly injections. As the data
were paired for individuals, an initial analysis using a
two-tailed paired sample t-test was used, which was fol-
lowed by a two-factor analysis of variance with a factor
for vignette and a factor for participant to test for overall
differences across the vignettes. As the distribution of the
data appeared to be not normally distributed, a more
conservative overall non-parametric test (Friedman’s)
was undertaken. Differences in utility values between
demographic factors and ordering effects were explored
with the Mann-Whitney U-test (two groups) or Kruskal-
Wallis test (two or more groups). All analyses were
undertaken using SPSS version 14 (SPSS Inc., Chicago,
IL, USA).
Results
Of the 124 individuals invited to participate, 98 (78.4%)
people were recruited and completed the TTO interview.
Fifty per cent were women, 45% reported that they were
single (unmarried, divorced or widowed), and about half
reported having an income less than AUD$50 000 (see
Table 1). Almost half (47%) of participants were under the
age of 40 and there was a wide distribution across educa-
tion groups, with about one quarter having completed
Osborne et al. Health and Quality of Life Outcomes 2012, 10:35
http://www.hqlo.com/content/10/1/35
Page 4 of 9Table 1 Health-related quality of life (utility) values for varying treatment intervals across demographic categories;
gender, age, income and education
Vignette 1: Untreated Vignette 2:
2 weeks
Vignette 3:
4 weeks
Vignette 4: 3 months
Gender
Men Mean .22 .57 .62 .70
(N = 49) Median .20 .60 .63 .75
SD .22 .24 .24 .22
Mean .32 .65 .69 .71
Women Median .25 .70 .75 .80
(N = 49) SD .30 .25 .23 .24
Z -1.45 -1.7 -1.6 -.5
p-value .15 .09 .11 .6
Age (years)
<30 Mean .23 .59 .65 .70
(N = 25) Median .18 .65 .70 .75
SD .23 .22 .22 .26
30-50 Mean .26 .60 .65 .71
(N = 42) Median .15 .63 .70 .75
SD .24 .24 .23 .22
>50 Mean .31 .62 .65 .70
(N = 30) Median .20 .70 .73 .79
SD .32 .29 .27 .27
Chi-Square .52 .91 .10 .13
df 2 2 2 2
p-value .8 .6 .9 .9
Income (AUD$)
<30,000 Mean .27 .62 .67 .71
(N = 36) Median .18 .65 .69 .73
SD .30 .24 .24 .22
$30,000- $80,000 Mean .24 .60 .65 .72
(N = 41) Median .18 .65 .70 .80
SD .24 .27 .24 .25
>$80,000 Mean .32 .60 .62 .67
(N = 21) Median .40 .65 .70 .70
SD .24 .23 .23 .22
Chi-Square 1.7 .16 .70 1.6
df 2 2 2 2
p-value .4 .9 .7 .4
Education
High school or less Mean .27 .62 .67 .73
(N = 25) Median .20 .68 .70 .80
SD .24 .23 .20 .21
TAFE or college Mean .27 .61 .67 .68
(N = 30) Median .08 .70 .73 .75
SD .31 .28 .26 .25
University graduate Mean .27 .58 .63 .70
(N = 41) Median .20 .60 .70 .75
SD .25 .25 .25 .23
Chi-Square 1.7 .16 .70 1.6
df 2 2 2 2
p-value .4 .9 .7 .4
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Page 5 of 9year 12 or less, one third having completed vocational
education, and the remainder having graduated from uni-
versity. Just over half were in full time employment and
the most common occupational group was business and
management (14%), followed byr e t a i la n ds a l e s( 1 3 % ) .
This sample approximates the age and gender mix of Aus-
tralians where the median age is 36.9 years and there are
approximately 13% of people over the age of 65 years [16].
As part of interview quality control in the current
study, each interviewee was observed for evidence that
they had either misunderstood the TTO process or pro-
vided illogical answers. Notes on substantive difficulties
an interviewee experienced were made at the conclusion
of the interview. No interviewees exhibited substantial
misunderstanding, therefore, all data were included in
the analysis.
Scores within each vignette were distributed across the
entire life/death scale, reflecting widely held beliefs or
reactions to trading years of life in the TTO exercise,
including the position of a minority of people who
refused to trade. The few individuals who refused to
trade or traded very little (i.e. with scores >0.80, n = 4)
can be seen in Figure 2, Vignette 1 (untreated schizo-
phrenia), at the extreme right of the dot plot. Given that
only a few people did not trade, data from all individuals
was included in the analysis.
Untreated schizophrenia was rated as the poorest
health-related quality of life. The treated health states
were all rated at much higher utility and there were
clear monotonic differences between the treatment vign-
ettes (see Table 2). Differences between the test vign-
ettes were all statistically significant for both ANOVA
and Friedman’st e s t( p < 0.001 for all comparisons) (See
Table 2). When compared with 2-weekly injections, 4-
weekly injections were associated with higher utility
(mean [95% CI] 0.047 [0.069-0.025]) and 2-weekly injec-
tions were associated with an even larger utility differ-
ence compared with 3-monthly injections (0.098 [0.129-
Figure 2 Frequency distribution of respondents scores across the four treatment regimens (0.0 = death equivalent health-related
quality of life, 1.0 = full health).
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3-monthly injections was also substantial (−0.051
[0.094-0.032]).
No systematic differences in utility scores were
observed when the order of vignette presentation was
considered. Kruskal-Wallis analyses were undertaken
across vignette presentation order and no patterns of bias
were observed (Untreated schizophrenia Chi sq = 2.6, p =
0.8; 2-weekly injections, Chi sq =0.6, p =0 . 7 ;4 - w e e k l y
injections, Chi sq = 0.9 p = 0.1; and 3-monthly injections,
Chi sq = 1.3 p = 0.9).
Discussion
This study sought to estimate the strength of preference
individuals place on receiving antipsychotic LAIs for
schizophrenia every two weeks, every four weeks or every
three months. People from the general population were
selected to obtain a societal perspective rather than a
patient-specific perspective. These community-based pre-
ferences reflect utility values as applied in economic eva-
luations and are more informative than patient-based
preferences when making judgments about the allocation
of societal resources within health care [14,15]. This is
the first study to assess the utility values associated with
varying injection frequencies of long-acting antipsychotic
treatment administered to patients with schizophrenia.
Our results show that community respondents strongly
preferred the health states in which patients receive anti-
psychotic LAIs less frequently, with a clear pattern of
increasing utility observed with increasing time between
injections. Administration every four weeks was preferred
to administration every two weeks. The mean utility value
associated with the health state for 4-weekly injections was
0.65 (median 0.70), indicating that respondents would be
prepared to give up 3.5 years of life out of 10 to live in per-
fect health. In contrast, having schizophrenia that is well-
controlled with 2-weekly injections is regarded as a less
optimal health state with participants willing to give up 4
years out of 10 to live in normal health. The mean differ-
ence between administration for both every two weeks
and every three months was 0.1 (median 0.1), equivalent
to a 10% difference in scale score. In quality of life
research, a change of 10% of a scale is regarded as at least
a minimal important difference [17]. The mean utility
value associated with the health state in which 3-monthly
injections were used was 0.70 (median 0.75), indicating
that respondents would be prepared to give up 3 years of
life out of 10 to live in perfect health. This implies that
most respondents regard having schizophrenia that is
well-controlled by 4-weekly or 3-monthly injections as
offering a better HRQoL than that controlled by 2-weekly
injections.
It is not surprising that participants would prefer less
frequent injections given the psychological distress and
pain associated with injections, as well as the burden
related to the requirement of travel to outpatient clinics
for their administration. However, this study provides
quantification of the ‘value’ of this preference; an impor-
tant consideration in health care funding decisions.
Briggs et al., examined the utility values for relapsed
schizophrenia health states in 49 people with stable schi-
zophrenia and in 75 laypersons using a TTO exercise
[ 1 8 ] .T h e yf o u n dp e o p l ew i t hs c h i z o p h r e n i aw e r el e s s
willing to trade than laypersons to avoid symptoms of
schizophrenia (0.60 and 0.45, respectively). The utility of
the relapsed state was assessed as less severe than in our
study, which may be explained by the severity of our (in
hospital) health state, which is substantially worse than
their relapse state where the subject is able to work part-
time.
Szende et al. [19] used a TTO exercise to investigate
preferences for transfusion independence, reduced trans-
fusions and transfusion-dependence in patients with
myelodysplastic syndrome. This study’sr e s u l t ss h o w e d
that utility scores for transfusion independence were sig-
nificantly higher than for reduced transfusions or transfu-
sion-dependence, with a utility difference of 0.17 between
reduced transfusions and transfusion dependence. In
another recent study, subcutaneous infusion compared
with once-daily oral administration of iron chelation
therapy in those with iron overload disorders showed a
significant impact of the route of drug administration on
the utility value that patients associate with treatment
[13]. In that study, utility differences of 0.23 were
reported, larger than were observed in the present study.
That the utility differences are smaller in the current
study is to be expected given the less marked differences
between treatment options and likely effect on health-
related quality of life compared to the other studies. TTO
methodology has also been used to estimate the utility
associated with three health states (fear of falling, a
“good” hip fracture, and a “bad” hip fracture) among
older women [20]. A"bad” hip fracture(which results in
admission to a nursing home) was valued at 0.05; a
“good” hip fracture (maintaining independent living in
the community) at 0.31, and fear of falling at 0.67. The
Table 2 Comparison of health-related quality of life
(utility) between vignettes of 2 week, 4 week and 3
month treatment regimens
Vignette Mean Median SD Min Max ANOVA Friedman
Test
Vignette 2 (2
weeks)
0.61 0.65 0.25 0.00 1.00 p<0.001 p<0.001
Vignette 3 (4
weeks)
0.65 0.70 0.24 0.00 1.00
Vignette 4 (3
monthly)
0.70 0.75 0.23 0.05 1.00
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dently in the community was associated with a consider-
ably reduced health-related quality of life. Similarly, the
use of antipsychotic LAIs, particularly those administered
less frequently may promote adherence with treatment,
and therefore independent living in the community in
those with schizophrenia.
In this study, we aimed to ensure the utilities extracted
by the TTO exercise resulted in consistent and reliable
data. In previous studies, acceptable reliability data have
been reported for the TTO technique where intraclass
correlation coefficient estimates ranged from 0.61 to 0.88
[20-22]. In the present study, relatively wide ranges of pre-
ference scores were observed for all LAI administration
intervals (Figure 2), but a clear pattern of higher utility
was observed with increasing time between injections. As
we presented only four TTO exercises to each participant
(untreated schizophrenia, 2-weekly, 4-weekly and 3-
monthly administration) there was the possibility of order-
ing effects. To prevent this from confounding the data we
included a randomization procedure for the latter three
vignettes (vignette one was always presented first).
A potential weakness of the study is the lack of popula-
tion-based sampling. The sample did include a number of
respondents from higher socioeconomic backgrounds.
This study incorporated a purposeful sampling in an
attempt to obtain a broad societal perspective, rather than
what might be regarded as more rigorous population-
based sampling approach. Although the sample did
include a substantial number of people from higher socio-
economic backgrounds, no differences in utility values
obtained were observed across demographic subgroups.
Recent privacy legislation and poor recruitment rates in
studies employing population-based sampling designs (as
low as 30% in some studies) make it an increasingly pro-
blematic sampling technique [23]. The study may also
have been improved through the inclusion of cognitive
debriefing interviews to ratify respondent’sa n s w e r sa n d
inclusion of formal test-retest studies to assess statistical
reliability of the TTO interviews.
For this study we chose to use TTO methodology that
complies with standard welfare economic principles that
individuals are the best judges of their own welfare.
There has been some debate in the literature concerning
the relative merits of the theoretical properties of TTO,
standard gamble and multi-attribute utility instruments,
however empirically they have been shown to produce
similar results. Some unresolved controversies remain
including uncertainty about participant assumptions
concerning their wealth when questions require trade-
offs over extended periods. It is also known that the
longer the period in question, the less likely respondents
are to trade.
Conclusions
In summary, this study has provided valuable insights into
what people regard as the potential advantage of LAIs.
These results indicate that society associates a higher uti-
lity with increasing time between injections, with 4-weekly
and 3-monthly administration of an antipsychotic LAI
representing an advance over 2-weekly administration in
the HRQoL of patients with schizophrenia. Approximately
a 0.05 utility advantage exists between 2-weekly, 4-weekly
and 3-monthly administration options considered, with
the highest utility assigned to 3-monthly injections. As
new medications that can be administered over 3-monthly
intervals are in development, the present results will pro-
vide important information to facilitate the economic eva-
luation of these drugs by isolating the benefit to patients
of this change in their regimen.
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